ClinicalTrials.gg
CompletedNCT01942161Updated Jun 28, 2017Results posted

A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

A Phase 2/3 interventional study of Aripiprazole Low (2 mg/day) and Aripiprazole Mid (6 - 12 mg/day) in Schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-28.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
72nd of 125
106 · median 130
Started
2010
with 5 others
Phase 2/3
4 of 126
none open now
Registered
80th of 126
by date
Lead sponsor
4 of 126
Otsuka Pharmaceutical Co., Ltd.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 72nd largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2010, is one of 4 in phase 2/3, and was the 80th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17 years) with schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schyzophrenia, pediatric patients
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of schizophrenia (295.30, 295.10, 295.20, 295.90, 295.60), according to DSM-Ⅳ-TR (M.I.N.I.KID will be used as backup)
  • Male and female patients aged 13-17 years (between IC and end of dosing)
  • Patients with a PANSS score of 70 or more [both at start of dosing (Day 1 and at baseline
  • Patients who, in addition to their legal guardian, provide written , having understood the details of this study
  • Inpatient or outpatient status

Exclusion criteria

Exclusion Criteria:

  • Patients who have a diagnosis of any other disease except schizophrenia, according to
  • Patients who have been compulsorily admitted to hospital
  • Patients with mental retardation
  • Patients with thyroid disorder
  • Patients who have a history of receiving treatment with clozapine, or who have received sufficient doses of two or more kinds of antipsychotic drug for more than four weeks but failed to respond to this treatment
  • Patients who have received a prohibited concomitant medication or therapy listed in table 6.4-1 after the start of the prohibited concomitant medication timeframe [to be confirmed at start of dosing (Day 1) and at baseline].
  • Patients who have a history of receiving treatment with aripiprazole
  • Patients who fall under a listed in the ABILIFY package insert
  • Patients with a serious hepatic, renal, cardiac or hematopoietic disorder
  • Patients with a history or a complication of organic brain disorder or convulsive disorder such as epilepsy
  • Patients with diabetes. and patients who fall under any of the following:

fasting blood glucose level ≧126 mg/dL, non-fasting blood glucose level ≧200 mg/dL, ≧6.5%

  • Patients with a history or a complication of suicide attempt, suicidal thought or self-harm
  • Patients with a score of ≧2(mild) on PART1 evaluation of CGI-SS
  • Patients with a history or a complication of malignant syndrome, tardive dyskinesia or paralytic ileus
  • Patients in a state of physical exhaustion accompanied by such conditions as dehydration or malnutrition
  • Patients with a history or a complication of water intoxication
  • Patients with Parkinson's disease
  • Pregnant women, parturient women, nursing women, women of who wish to become pregnant during this trial. However, women of childbearing potential who are practicing an appropriate method of and have a negative pregnancy test result are eligible for inclusion in this study.
  • Patients who have a diagnosis of a substance-related disorder according to DSM-Ⅳ-TR within the past 3 months
  • Patients with a positive drug screen (urine) result
  • Study enrollment is otherwise judged to be inappropriate by the Investigator or Subinvestigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Low (2 mg/day)

    Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).

    Drug: Aripiprazole Low (2 mg/day)

  • Experimental
    Mid (6 - 12 mg/day)

    Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.

    Drug: Aripiprazole Mid (6 - 12 mg/day)

  • Experimental
    High (24 - 30 mg/day)

    Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.

    Drug: Aripiprazole High (24 - 30 mg/day)

Interventions

  • DrugAripiprazole Low (2 mg/day)

    Drug page: Aripiprazole

    administered 2 mg once daily for 6 weeks

    Also known as: Aripiprazole

  • DrugAripiprazole Mid (6 - 12 mg/day)

    Drug page: Aripiprazole

    administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg

    Also known as: Aripiprazole

  • DrugAripiprazole High (24 - 30 mg/day)

    Drug page: Aripiprazole

    administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg

    Also known as: Aripiprazole

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7: 1 =Absent, 2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme. PANSS total score is calculated by adding score of 30 items, which ranges from 30-210. Higher scores indicate worse condition.

    Time frame: Baseline (Day 1) and Day 43

Secondary outcomes

  1. Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Total Score

    The Positive and Negative Syndrome Scale (PANSS) positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49, with higher values indicating worse condition.

    Time frame: Baseline (Day 1) and Day 43

  2. Mean Change From Baseline at Final Assessment in Clinical Global Impression-Severity of Illness (CGI-S) Score

    The Clinical Global Impression-Severity of Illness (CGI-S) Score is a clinician rated scale which assesses how mentally ill the patient is at the time. Scores range from 0 to 7: 0 = Not assessed, 1= Normal, not at all ill, 2 =Borderline mentally ill, 3= Mildly ill, 4= Moderately ill, 5= Markedly ill, 6= Severely ill, 7= Among the most extremely ill patients. Higher scores indicate worse condition.

    Time frame: Baseline (Day 1) and Day43

  3. Mean Change From Baseline at Final Assessment in Clinical Global Impression-Improvement (CGI-I) Score

    The Clinical Global Impression-Improvement (CGI-I) Score is a clinician rated scale which assesses the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

    Time frame: Baseline (Day 1) and day43

  4. Mean Change From Baseline at Final Assessment in Children's Global Assessment Scale (C-GAS) Score

    The Children's Global Assessment Scale (C-GAS) is a rating scale which measures psychological, social and school functioning for children aged 6-17. Scores range from 0 to 100, with higher scores indicating better condition.

    Time frame: Baseline (Day 1) and Day 43

07

Results

Posted Jun 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
Started353041
Completed272435
Not completed866
Withdrew: Adverse event125
Withdrew: Physician decision310
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject331

Outcome measures

PrimaryMean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score

The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7: 1 =Absent, 2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme. PANSS total score is calculated by adding score of 30 items, which ranges from 30-210. Higher scores indicate worse condition.

Time frame:
Baseline (Day 1) and Day 43
Reported as:
Mean · units on a scale
Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score-19.6 ± 3.2-16.5 ± 3.5-21.6 ± 3.0
SecondaryMean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Total Score

The Positive and Negative Syndrome Scale (PANSS) positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49, with higher values indicating worse condition.

Time frame:
Baseline (Day 1) and Day 43
Reported as:
Mean · units on a scale
Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Total Score
units on a scaleLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Total Score-5.2 ± 0.8-4.9 ± 0.9-5.8 ± 0.8
SecondaryMean Change From Baseline at Final Assessment in Clinical Global Impression-Severity of Illness (CGI-S) Score

The Clinical Global Impression-Severity of Illness (CGI-S) Score is a clinician rated scale which assesses how mentally ill the patient is at the time. Scores range from 0 to 7: 0 = Not assessed, 1= Normal, not at all ill, 2 =Borderline mentally ill, 3= Mildly ill, 4= Moderately ill, 5= Markedly ill, 6= Severely ill, 7= Among the most extremely ill patients. Higher scores indicate worse condition.

Time frame:
Baseline (Day 1) and Day43
Reported as:
Mean · units on a scale
Mean Change From Baseline at Final Assessment in Clinical Global Impression-Severity of Illness (CGI-S) Score
units on a scaleLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
Mean Change From Baseline at Final Assessment in Clinical Global Impression-Severity of Illness (CGI-S) Score-0.9 ± 0.2-0.8 ± 0.2-1.0 ± 0.2
SecondaryMean Change From Baseline at Final Assessment in Clinical Global Impression-Improvement (CGI-I) Score

The Clinical Global Impression-Improvement (CGI-I) Score is a clinician rated scale which assesses the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

Time frame:
Baseline (Day 1) and day43
Reported as:
Mean · units on a scale
Mean Change From Baseline at Final Assessment in Clinical Global Impression-Improvement (CGI-I) Score
units on a scaleLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
Mean Change From Baseline at Final Assessment in Clinical Global Impression-Improvement (CGI-I) Score3.0 ± 0.23.2 ± 0.22.7 ± 0.2
SecondaryMean Change From Baseline at Final Assessment in Children's Global Assessment Scale (C-GAS) Score

The Children's Global Assessment Scale (C-GAS) is a rating scale which measures psychological, social and school functioning for children aged 6-17. Scores range from 0 to 100, with higher scores indicating better condition.

Time frame:
Baseline (Day 1) and Day 43
Reported as:
Mean · units on a scale
Mean Change From Baseline at Final Assessment in Children's Global Assessment Scale (C-GAS) Score
units on a scaleLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
Mean Change From Baseline at Final Assessment in Children's Global Assessment Scale (C-GAS) Score10.5 ± 2.08.5 ± 2.18.6 ± 1.8

Adverse events

Collected over From the start date of screening examination to date of the final examination (up to Week 6 at e hours after IMP administration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low (2 mg/Day)—0/35 (0%)29/35 (82.9%)
Mid (6 - 12 mg/Day)—2/30 (6.7%)28/30 (93.3%)
High (24 - 30 mg/Day)—2/41 (4.9%)38/41 (92.7%)
Most frequent serious events
Most frequent serious events
EventLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
SchizophreniaPsychiatric disorders0/351/300/41
Suicide attemptPsychiatric disorders0/351/301/41
AnxietyPsychiatric disorders0/350/301/41
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLow (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)
NauseaGastrointestinal disorders7/354/309/41
SomnolenceNervous system disorders5/356/305/41
InsomniaPsychiatric disorders5/356/307/41
Salivary hypersecretionGastrointestinal disorders1/351/306/41
TremorNervous system disorders3/353/306/41
NasopharyngitisInfections and infestations5/354/305/41
EpistaxisRespiratory, thoracic and mediastinal disorders2/354/300/41
MalaiseGeneral disorders3/353/302/41
ContusionInjury, poisoning and procedural complications0/353/300/41
Decreased appetiteMetabolism and nutrition disorders0/353/303/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Low (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)Total
<=18 years353041106
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)Low (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)Total
Mean15.1 ± 1.415.4 ± 1.314.7 ± 1.315.0 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)Low (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)Total
Female21112355
Male14191851
Region of Enrollment
Region of Enrollment(participants)Low (2 mg/Day)Mid (6 - 12 mg/Day)High (24 - 30 mg/Day)Total
Japan353041106
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kansai Region, Japan
  • Kanto Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2013
First posted
Sep 13, 2013
Start
Aug 2010
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Jun 28, 2017
Last update
Jun 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01942161
Responsible party
Sponsor
First posted
Sep 13, 2013
Start date
Aug 2010
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Jun 28, 2017
Last update
Jun 28, 2017

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion